| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER–Medicare analysis
|
Malhotra, J.
|
|
|
26 |
4 |
p. 768-773
|
artikel
|
| 2 |
Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all
|
Cervantes, A.
|
|
|
26 |
4 |
p. 617-619
|
artikel
|
| 3 |
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial †
|
Breugom, A.J.
|
|
|
26 |
4 |
p. 696-701
|
artikel
|
| 4 |
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
|
Lim, S.H.
|
|
|
26 |
4 |
p. 762-768
|
artikel
|
| 5 |
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
|
Bellmunt, J.
|
|
|
26 |
4 |
p. 812-817
|
artikel
|
| 6 |
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage
|
Findlay, J.M.
|
|
|
26 |
4 |
p. 624-644
|
artikel
|
| 7 |
Atypical femur fractures associated with use of bisphosphonates and denosumab
|
Farooki, A.
|
|
|
26 |
4 |
p. 819-820
|
artikel
|
| 8 |
Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
|
Lorente, D.
|
|
|
26 |
4 |
p. 750-755
|
artikel
|
| 9 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
|
Koeberle, D.
|
|
|
26 |
4 |
p. 709-714
|
artikel
|
| 10 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
|
Gruenberger, T.
|
|
|
26 |
4 |
p. 702-708
|
artikel
|
| 11 |
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
|
Morelli, M.P.
|
|
|
26 |
4 |
p. 731-736
|
artikel
|
| 12 |
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
|
Masi, G.
|
|
|
26 |
4 |
p. 724-730
|
artikel
|
| 13 |
Contralateral biopsies in patients with testicular germ-cell tumour—nuisance or new sense?
|
Dieckmann, K.-P.
|
|
|
26 |
4 |
p. 620-621
|
artikel
|
| 14 |
Designs of drug-combination phase I trials in oncology: a systematic review of the literature
|
Riviere, M.-K.
|
|
|
26 |
4 |
p. 669-674
|
artikel
|
| 15 |
Different adjuvant chemotherapy regimens in older breast cancer patients?
|
Wildiers, H.
|
|
|
26 |
4 |
p. 613-615
|
artikel
|
| 16 |
Editorial board
|
|
|
|
26 |
4 |
p. ii-iii
|
artikel
|
| 17 |
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?
|
Malvezzi, M.
|
|
|
26 |
4 |
p. 779-786
|
artikel
|
| 18 |
Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer risk
|
Samoli, E.
|
|
|
26 |
4 |
p. 793-797
|
artikel
|
| 19 |
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials
|
Haller, D.G.
|
|
|
26 |
4 |
p. 715-724
|
artikel
|
| 20 |
Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis
|
Pita-Fernández, S.
|
|
|
26 |
4 |
p. 644-656
|
artikel
|
| 21 |
Low-dose aspirin use and the risk of ovarian cancer in Denmark
|
Baandrup, L.
|
|
|
26 |
4 |
p. 787-792
|
artikel
|
| 22 |
Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomakers?
|
Castro, E.
|
|
|
26 |
4 |
p. 622-623
|
artikel
|
| 23 |
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials †
|
van Soest, R.J.
|
|
|
26 |
4 |
p. 743-749
|
artikel
|
| 24 |
Obesity and cancer: links with survival differ from those with incidence
|
Renehan, A.G.
|
|
|
26 |
4 |
p. 821
|
artikel
|
| 25 |
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
|
Bendell, J.
|
|
|
26 |
4 |
p. 804-811
|
artikel
|
| 26 |
Postoperative surveillance in nonmetastatic colorectal cancer patients: yes, but…
|
Castells, A.
|
|
|
26 |
4 |
p. 615-617
|
artikel
|
| 27 |
Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes
|
Kote-Jarai, Z.
|
|
|
26 |
4 |
p. 756-761
|
artikel
|
| 28 |
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
|
Thaler, Josef
|
|
|
26 |
4 |
p. 822-825
|
artikel
|
| 29 |
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes †
|
Giannatempo, P.
|
|
|
26 |
4 |
p. 657-668
|
artikel
|
| 30 |
Reply to the letter to the editor ‘Albumin to globulin ratio, a predictor or a misleader?’ by Alkan et al.
|
Suh, B.
|
|
|
26 |
4 |
p. 820-821
|
artikel
|
| 31 |
Reply to the letter to the editor ‘Surrogate end points for overall survival.Festina lente (more haste, less speed)’ by Braillon
|
Maeda, H.
|
|
|
26 |
4 |
p. 818-819
|
artikel
|
| 32 |
Risk of subsequentin situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinomain situ
|
Curigliano, G.
|
|
|
26 |
4 |
p. 682-687
|
artikel
|
| 33 |
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis
|
Aapro, M.
|
|
|
26 |
4 |
p. 688-695
|
artikel
|
| 34 |
Screening for carcinomain situ in the contralateral testicle in patients with testicular cancer: a population-based study
|
Kier, M.G.G.
|
|
|
26 |
4 |
p. 737-742
|
artikel
|
| 35 |
Surrogate end points for overall survival.Festina lente (more haste, less speed)
|
Braillon, A.
|
|
|
26 |
4 |
p. 818
|
artikel
|
| 36 |
Table of Contents
|
|
|
|
26 |
4 |
p. iv-vi
|
artikel
|
| 37 |
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
|
Di Giacomo, A.M.
|
|
|
26 |
4 |
p. 798-803
|
artikel
|
| 38 |
Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
|
Horwitz, S.
|
|
|
26 |
4 |
p. 774-779
|
artikel
|
| 39 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
|
Perrone, F.
|
|
|
26 |
4 |
p. 675-682
|
artikel
|
Tijdschrift beschrijving